In this presentation from Lymphoma & Myeloma 2016, Dr. Alison Moskowitz argues in favor of the use of serial novel agents (including brentuximab and checkpoint inhibitors) for a Hodgkin lymphoma patents who relapses after autologous stem cell transplant.
Click to Earn CME Credit: http://bit.ly/2mFKBrY
© 2016 Imedex, LLC.
Advertisement